CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 9 enrolled
Drug / intervention
Perflubutane Microbubble +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05105087
NCT05105087Early Ph 1Completed

Detection of Sentinel Lymph Nodes in Female Lower Genital Tract Cancer Patients With Contrast-Enhanced Ultrasound Imaging

Thomas Jefferson University·interventional·Posted Nov 3, 2021·Updated Aug 22, 2025

In Brief

A Early Phase 1 clinical trial evaluating Perflubutane Microbubble and Contrast-Enhanced Ultrasound for Cervical Carcinoma and 3 related conditions. Completed, enrolled 9 participants across 1 site.

Detailed Summary

This clinical trial compares the use of ultrasound for the detection of sentinel lymph nodes (SLNs) to the standard of care (which varies depending on cancer treatment). The ultrasound contrast agent is called Sonazoid and it consists of tiny gas-filled bubbles about the side of red blood cells. Diagnostic procedures, such as ultrasound with Sonazoid, may help identify more SLNs than standard of care in patients with cervical, vaginal, or vulvar cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Early Ph 1CompletedFinished
20222023202420252026
First PostedNov 3, 2021
Enrollment StartApr 28, 2022
Primary CompletionNov 15, 2023
Study CompletionJan 29, 2025
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4.7 years ago

Interventions

Perflubutane Microbubbledrug

Given subdermally

Contrast-Enhanced Ultrasoundprocedure

Undergo ultrasound